Verrica Pharmaceuticals Inc (NASDAQ: VRCA) kicked off on Monday, up 12.11% from the previous trading day, before settling in for the closing price of $4.21. Over the past 52 weeks, VRCA has traded in a range of $3.28-$13.60.
During the last 5-year period, the sales drop of Healthcare Sector giant was -5.46%. While this was happening, its average annual earnings per share was recorded 93.58%. With a float of $3.83 million, this company’s outstanding shares have now reached $9.49 million.
Verrica Pharmaceuticals Inc (VRCA) Breakdown of a Key Holders of the stock
Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of Verrica Pharmaceuticals Inc is 59.64%, while institutional ownership is 29.45%. The most recent insider transaction that took place on Mar 17 ’25, was worth 2,805. In this transaction CHIEF LEGAL OFFICER of this company sold 4,315 shares at a rate of $0.65, taking the stock ownership to the 176,458 shares.
Verrica Pharmaceuticals Inc (VRCA) Recent Fiscal highlights
In the latest quarterly report, which was put into the public domain on 12/31/2024, the organization reported -2.01 earnings per share (EPS), higher than consensus estimate (set at -2.42) by 0.41. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.58 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 93.58% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 58.54% during the next five years compared to -5.46% drop over the previous five years of trading.
Verrica Pharmaceuticals Inc (NASDAQ: VRCA) Trading Performance Indicators
Take a look at Verrica Pharmaceuticals Inc’s (VRCA) current performance indicators. Last quarter, stock had a quick ratio of 1.11. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 1.45.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -3.44, a number that is poised to hit -0.68 in the next quarter and is forecasted to reach -1.61 in one year’s time.
Technical Analysis of Verrica Pharmaceuticals Inc (VRCA)
Looking closely at Verrica Pharmaceuticals Inc (NASDAQ: VRCA), its last 5-days average volume was 0.22 million, which is a jump from its year-to-date volume of 0.12 million. As of the previous 9 days, the stock’s Stochastic %D was 57.15%.
During the past 100 days, Verrica Pharmaceuticals Inc’s (VRCA) raw stochastic average was set at 23.15%, which indicates a significant decrease from 74.86% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 0.39 in the past 14 days, which was lower than the 0.50 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $4.07, while its 200-day Moving Average is $5.46. However, in the short run, Verrica Pharmaceuticals Inc’s stock first resistance to watch stands at $5.13. Second resistance stands at $5.55. The third major resistance level sits at $5.91. If the price goes on to break the first support level at $4.35, it is likely to go to the next support level at $3.99. Now, if the price goes above the second support level, the third support stands at $3.57.
Verrica Pharmaceuticals Inc (NASDAQ: VRCA) Key Stats
The company with the Market Capitalisation of 44.79 million has total of 9,490K Shares Outstanding. Its annual sales at the moment are 7,570 K in contrast with the sum of -76,580 K annual income. Company’s last quarter sales were recorded 14,340 K and last quarter income was -270 K.
